株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

骨粗鬆症治療薬の世界市場

Osteoporosis Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 912424
出版日 ページ情報 英文 340 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

骨粗鬆症治療薬の世界市場 Osteoporosis Therapeutics
出版日: 2019年11月01日 ページ情報: 英文 340 Pages
概要

当レポートでは、世界における骨粗鬆症治療薬市場の概要、動向・発展への影響因子の分析、競合企業と市場シェア、世界および地域・主要国別の市場規模の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
    • 世界市場における企業シェア
    • 世界の骨粗鬆症治療薬市場における企業シェアのシナリオ
  • 主要企業
  • 市場の動向と発展因子
  • 世界市場の見通し

第3章 市場分析

  • 地域別市場の分析
    • 米国
    • カナダ
    • 日本
    • 中国
    • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他欧州
    • アジア太平洋地域
    • オーストラリア
    • インド
    • 韓国
    • その他アジア太平洋地域
    • ラテンアメリカ
    • アルゼンチン
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ
    • 中東
    • イラン
    • イスラエル
    • サウジアラビア
    • アラブ首長国連邦
    • その他中東
    • アフリカ

第4章 競合企業

  • ALLERGAN PLC
  • AMGEN
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • PFIZER
  • TEVA PHARMACEUTICAL INDUSTRIES

第5章 調査資料

目次
Product Code: MCP-1229

Osteoporosis Therapeutics market worldwide is projected to grow by US$2.5 Billion, driven by a compounded growth of 3%. Bisphosphonates, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.2%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$6.9 Billion by the year 2025, Bisphosphonates will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 2.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$153.9 Million to the region's size and clout in the next 5 to 6 years. Over US$193.2 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Bisphosphonates will reach a market size of US$1.3 Billion by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.9% over the next couple of years and add approximately US$229.1 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include among others, Alergan Plc. (Ireland); Amgen, Inc. (US); Chugai pharmaceutical (Japan); Daiichi Sankyo Co., Ltd.(Japan); Egalet Corporation (USA); Eisai Co., Ltd. (Japan); Eli Lilly and Company (US); F. Hoffmann-La Roche Ltd. (Switzerland);

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE 1

II. EXECUTIVE SUMMARY 12

1. MARKET OVERVIEW 12

  • A Prelude to Osteoporosis 12
  • Select Approved Drugs for Treatment of Osteoporosis 12
  • Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market 13
  • Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth 13
  • Global Competitor Drug Sales 14
  • Sales of Leading Osteoporosis Therapeutics: 2018 14
  • Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis 14
  • Select Recent Osteoporosis Drug Approvals 15

2. FOCUS ON SELECT PLAYERS 16

  • Amgen, Inc. (USA) 16
  • Chugai Pharmaceutical Co., Ltd. (Japan) 16
  • Daiichi Sankyo Co., Ltd. (Japan) 16
  • Eisai Co., Ltd. (Japan) 17
  • Eli Lilly and Company (USA) 17
  • F. Hoffmann-La Roche Ltd. (Switzerland) 18
  • Merck & Co. Inc. (USA) 18
  • Novartis International AG (Switzerland) 18
  • Pfizer, Inc. (USA) 19
  • Radius Health, Inc. (USA) 19

3. MARKET TRENDS & DRIVERS 20

  • Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics 20
  • Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India 20
  • % of Women Affected by Osteoporosis 21
  • Osteoporosis - Factsheet 21
  • Osteoporosis in Men 22
  • Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains 22
  • Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025 23
  • Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth 23
  • Changing Lifestyle Impacting Bone Health 24
  • Recommended Daily Intake of Calcium and Vitamin D 25
  • Increasing Awareness Related to Osteoporosis Care 25
  • New Product Launches Foster Market Growth 26

4. GLOBAL MARKET PERSPECTIVE 27

  • TABLE 1: Osteoporosis Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 27
  • TABLE 2: Osteoporosis Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 28
  • TABLE 3: Osteoporosis Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 29
  • TABLE 4: Bisphosphonates (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025 30
  • TABLE 5: Bisphosphonates (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 31
  • TABLE 6: Bisphosphonates (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 32
  • TABLE 7: Parathyroid Hormone Therapy (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 33
  • TABLE 8: Parathyroid Hormone Therapy (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 34
  • TABLE 9: Parathyroid Hormone Therapy (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 35
  • TABLE 10: Calcitonin (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 36
  • TABLE 11: Calcitonin (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 37
  • TABLE 12: Calcitonin (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 38
  • TABLE 13: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 39
  • TABLE 14: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 40
  • TABLE 15: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 41
  • TABLE 16: Rank Ligand Inhibitors (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025 42
  • TABLE 17: Rank Ligand Inhibitors (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 43
  • TABLE 18: Rank Ligand Inhibitors (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 44
  • TABLE 19: Oral (Route of Administration) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 45
  • TABLE 20: Oral (Route of Administration) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 46
  • TABLE 21: Oral (Route of Administration) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 47
  • TABLE 22: Injectables (Route of Administration) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 48
  • TABLE 23: Injectables (Route of Administration) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 49
  • TABLE 24: Injectables (Route of Administration) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 50
  • TABLE 25: Other Routes of Administration (Route of Administration) World Market by Region/Country in US$ Million: 2018 to 2025 51
  • TABLE 26: Other Routes of Administration (Route of Administration) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 52
  • TABLE 27: Other Routes of Administration (Route of Administration) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 53

III. MARKET ANALYSIS 54

  • GEOGRAPHIC MARKET ANALYSIS 54
  • UNITED STATES 54
    • TABLE 28: United States Osteoporosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 54
    • TABLE 29: Osteoporosis Therapeutics Market in the United States by Drug Class:
    • A Historic Review in US$ Million for 2009-2017 55
    • TABLE 30: United States Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 56
    • TABLE 31: United States Osteoporosis Therapeutics Market Estimates and Projections in US$ Million by Route of Administration: 2018 to 2025 57
    • TABLE 32: Osteoporosis Therapeutics Market in the United States by Route of Administration: A Historic Review in US$ Million for 2009-2017 58
    • TABLE 33: United States Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 59
  • CANADA 60
    • TABLE 34: Canadian Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 60
    • TABLE 35: Canadian Osteoporosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 61
    • TABLE 36: Osteoporosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 62
    • TABLE 37: Canadian Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018 to 2025 63
    • TABLE 38: Canadian Osteoporosis Therapeutics Historic Market Review by Route of Administration in US$ Million: 2009-2017 64
    • TABLE 39: Osteoporosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025 65
  • JAPAN 66
    • TABLE 40: Japanese Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 66
    • TABLE 41: Osteoporosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 67
    • TABLE 42: Japanese Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 68
    • TABLE 43: Japanese Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Route of Administration for the Period 2018-2025 69
    • TABLE 44: Osteoporosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Route of Administration for the Period 2009-2017 70
    • TABLE 45: Japanese Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 71
  • CHINA 72
    • TABLE 46: Chinese Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 72
    • TABLE 47: Osteoporosis Therapeutics Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017 73
    • TABLE 48: Chinese Osteoporosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 74
    • TABLE 49: Chinese Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Route of Administration for the Period 2018-2025 75
    • TABLE 50: Osteoporosis Therapeutics Historic Market Analysis in China in US$ Million by Route of Administration: 2009-2017 76
    • TABLE 51: Chinese Osteoporosis Therapeutics Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025 77
  • EUROPE 78
    • TABLE 52: European Osteoporosis Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025 78
    • TABLE 53: Osteoporosis Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 79
    • TABLE 54: European Osteoporosis Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 80
    • TABLE 55: European Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 81
    • TABLE 56: Osteoporosis Therapeutics Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 82
    • TABLE 57: European Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 83
    • TABLE 58: European Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018-2025 84
    • TABLE 59: Osteoporosis Therapeutics Market in Europe in US$ Million by Route of Administration: A Historic Review for the Period 2009-2017 85
    • TABLE 60: European Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 86
  • FRANCE 87
    • TABLE 61: Osteoporosis Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 87
    • TABLE 62: French Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 88
    • TABLE 63: French Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 89
    • TABLE 64: Osteoporosis Therapeutics Market in France by Route of Administration: Estimates and Projections in US$ Million for the Period 2018-2025 90
    • TABLE 65: French Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Route of Administration: 2009-2017 91
    • TABLE 66: French Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 92
  • GERMANY 93
    • TABLE 67: Osteoporosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 93
    • TABLE 68: German Osteoporosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 94
    • TABLE 69: German Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 95
    • TABLE 70: Osteoporosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Route of Administration for the Period 2018-2025 96
    • TABLE 71: German Osteoporosis Therapeutics Historic Market Analysis in US$ Million by Route of Administration: 2009-2017 97
    • TABLE 72: German Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 98
  • ITALY 99
    • TABLE 73: Italian Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 99
    • TABLE 74: Osteoporosis Therapeutics Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017 100
    • TABLE 75: Italian Osteoporosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 101
    • TABLE 76: Italian Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Route of Administration for the Period 2018-2025 102
    • TABLE 77: Osteoporosis Therapeutics Historic Market Analysis in Italy in US$ Million by Route of Administration: 2009-2017 103
    • TABLE 78: Italian Osteoporosis Therapeutics Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025 104
  • UNITED KINGDOM 105
    • TABLE 79: United Kingdom Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 105
    • TABLE 80: Osteoporosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 106
    • TABLE 81: United Kingdom Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 107
    • TABLE 82: United Kingdom Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Route of Administration for the Period 2018-2025 108
    • TABLE 83: Osteoporosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Route of Administration for the Period 2009-2017 109
    • TABLE 84: United Kingdom Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 110
  • REST OF EUROPE 111
    • TABLE 85: Rest of Europe Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 111
    • TABLE 86: Osteoporosis Therapeutics Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 112
    • TABLE 87: Rest of Europe Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 113
    • TABLE 88: Rest of Europe Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018-2025 114
    • TABLE 89: Osteoporosis Therapeutics Market in Rest of Europe in US$ Million by Route of Administration: A Historic Review for the Period 2009-2017 115
    • TABLE 90: Rest of Europe Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025 116
  • ASIA-PACIFIC 117
    • TABLE 91: Osteoporosis Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 117
    • TABLE 92: Asia-Pacific Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 118
    • TABLE 93: Asia-Pacific Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 119
    • TABLE 94: Osteoporosis Therapeutics Market in Asia-Pacific by Route of Administration: Estimates and Projections in US$ Million for the Period 2018-2025 120
    • TABLE 95: Asia-Pacific Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Route of Administration: 2009-2017 121
    • TABLE 96: Asia-Pacific Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025 122
  • REST OF WORLD 123
    • TABLE 97: Rest of World Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 123
    • TABLE 98: Rest of World Osteoporosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 124
    • TABLE 99: Osteoporosis Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 125
    • TABLE 100: Rest of World Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018 to 2025 126
    • TABLE 101: Rest of World Osteoporosis Therapeutics Historic Market Review by Route of Administration in US$ Million: 2009-2017 127
    • TABLE 102: Osteoporosis Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025 128

IV. COMPETITION 129

1. ALLERGAN PLC 129

2. AMGEN ASTELLAS BIOPHARMA K.K. 141

3. AMGEN, INC. 143

4. ASAHI KASEI PHARMA CORPORATION 152

5. BONE BIOLOGICS 154

6. CHUGAI PHARMACEUTICAL CO., LTD. 158

7. CLINIGEN GROUP PLC 167

  • NOVAGEN PHARMA (PTY) LTD. 175

8. DAIICHI SANKYO CO., LTD. 176

9. DONG WHA PHARMA CO., LTD. 184

10. EISAI CO., LTD. 185

11. ELI LILLY AND COMPANY 189

  • ELI LILLY CANADA, INC. 195
  • ELI LILLY AND CO., LTD. 196
  • ELI LILLY AUSTRALIA 196

12. ENTERA BIO LTD. 197

13. ENTERIS BIOPHARMA, INC. 198

14. ENZO BIOCHEM INC. 202

15. F. HOFFMANN-LA ROCHE AG 208

  • GENENTECH, INC. 217

16. FLEXION THERAPEUTICS, INC. 223

17. GEDEON RICHTER PLC 226

18. HAOMA MEDICA LTD. 235

19. IMMUNWORK INC. 236

20. INTAS PHARMACEUTICALS LTD. 240

21. LIGAND PHARMACEUTICALS INC. 241

22. LUYE PHARMA GROUP LTD. 251

23. MABXIENCE HOLDING SL 255

24. MERCK & CO., INC. 255

  • MERCK CANADA INC. 264

25. NOVARTIS INTERNATIONAL AG 266

  • NOVARTIS PHARMACEUTICALS CORPORATION 268

26. NOVEN PHARMACEUTICALS, INC. 270

27. ONO PHARMACEUTICAL CO., LTD. 272

28. PARAS BIOPHARMACEUTICALS FINLAND OY 276

29. PFENEX, INC. 278

30. PFIZER, INC. 285

31. R PHARM JSC 288

32. RADIUS HEALTH INC. 289

33. SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO. 291

34. SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 296

35. SHIN POONG PHARM CO., LTD. 300

36. SINIL PHARMACEUTICAL CO., LTD. 302

37. STADA ARZNEIMITTEL AG 303

38. STELIS BIOPHARMA PVT LTD. 305

39. TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. 305

40. TAKEDA PHARMACEUTICAL COMPANY LIMITED 310

41. TEIJIN PHARMA LTD. 314

42. TZAMAL BIO PHARMA LTD. 317

43. UNI-BIO SCIENCE GROUP LTD. 320

44. VIKING THERAPEUTICS, INC. 325

45. VIROMED CO., LTD. 328

46. ZYDUS CADILA HEALTHCARE 330